DK1838716T3 - Olanzapinpamota-dihydrat - Google Patents

Olanzapinpamota-dihydrat

Info

Publication number
DK1838716T3
DK1838716T3 DK05855335.5T DK05855335T DK1838716T3 DK 1838716 T3 DK1838716 T3 DK 1838716T3 DK 05855335 T DK05855335 T DK 05855335T DK 1838716 T3 DK1838716 T3 DK 1838716T3
Authority
DK
Denmark
Prior art keywords
dihydrate
olanzapinpamota
schizophrenia
pharmaceutical compositions
relates
Prior art date
Application number
DK05855335.5T
Other languages
English (en)
Inventor
Julie Kay Bush
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36024754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1838716(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DK1838716T3 publication Critical patent/DK1838716T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
DK05855335.5T 2005-01-05 2005-12-22 Olanzapinpamota-dihydrat DK1838716T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64169305P 2005-01-05 2005-01-05
PCT/US2005/046752 WO2006073886A1 (en) 2005-01-05 2005-12-22 Olanzapine pamoate dihydrate

Publications (1)

Publication Number Publication Date
DK1838716T3 true DK1838716T3 (da) 2011-07-25

Family

ID=36024754

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05855335.5T DK1838716T3 (da) 2005-01-05 2005-12-22 Olanzapinpamota-dihydrat

Country Status (11)

Country Link
US (1) US7932249B2 (da)
EP (1) EP1838716B1 (da)
JP (1) JP4940152B2 (da)
AT (1) ATE511512T1 (da)
CY (1) CY1111762T1 (da)
DK (1) DK1838716T3 (da)
ES (1) ES2363364T3 (da)
PL (1) PL1838716T3 (da)
PT (1) PT1838716E (da)
SI (1) SI1838716T1 (da)
WO (1) WO2006073886A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
ES2363364T3 (es) 2005-01-05 2011-08-02 Eli Lilly And Company Dihidrato de pamoato de olanzapina.
WO2011091142A2 (en) * 2010-01-20 2011-07-28 Teva Pharmaceutical Industries Ltd. Crystalline and amorphous forms of olanzapine pamoate
US9132136B2 (en) * 2010-08-02 2015-09-15 Hoffmann-La Roche Inc. Pharmaceutical combination
WO2012053654A1 (en) 2010-10-18 2012-04-26 Dainippon Sumitomo Pharma Co., Ltd. Sustained-release formulation for injection
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3735223A4 (en) 2018-01-05 2021-10-13 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
TWI756536B (zh) * 2019-04-12 2022-03-01 佳勝科技股份有限公司 改質液晶高分子的製作方法、液晶高分子組合物及改變液晶高分子之熔點的方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3354036A (en) 1963-11-19 1967-11-21 Du Pont Method of producing depression
GB1343936A (en) 1970-07-21 1974-01-16 Endo Lab Narcotic antagonist compositions having prolonged activity
US3676557A (en) 1971-03-02 1972-07-11 Endo Lab Long-acting narcotic antagonist formulations
ES410734A1 (es) 1973-01-18 1976-01-01 Rocador Sa Procedimiento para la obtencion del pamoato de butacaina.
US3895111A (en) 1973-06-27 1975-07-15 American Cyanamid Co Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate
US4016273A (en) 1975-07-16 1977-04-05 American Cyanamid Company Sustained release forms of certain oxazepines for parenteral administration
US4076942A (en) 1975-10-01 1978-02-28 Merck & Co., Inc. Crystalline dipilocarpinium pamoate
GB1539277A (en) 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
US4320124A (en) 1980-10-17 1982-03-16 Pfizer Inc. Composition for enhancing binding of a benzodiazepine to central benzodiazepine receptors and use thereof
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4906474A (en) 1983-03-22 1990-03-06 Massachusetts Institute Of Technology Bioerodible polyanhydrides for controlled drug delivery
DE3324192A1 (de) 1983-07-05 1985-01-17 Troponwerke Gmbh & Co Kg Depot-antiphlogistika
US4816247A (en) 1985-09-11 1989-03-28 American Cyanamid Company Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs
US4784845A (en) 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
GB2209937B (en) 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
US5292760A (en) 1987-12-07 1994-03-08 Hoechst-Roussel Pharmaceuticals Inc. 4-heteroaryl-1,3-benzodiazepines and 2-substituted-α-(heteroaryl)benzeneethanamines
JPH01284333A (ja) 1988-05-11 1989-11-15 T Hasegawa Co Ltd 乳化液組成物
GB8819059D0 (en) 1988-08-11 1988-09-14 Lilly Industries Ltd Benzodiazepine compounds & their use as pharmaceuticals
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5439688A (en) 1989-07-28 1995-08-08 Debio Recherche Pharmaceutique S.A. Process for preparing a pharmaceutical composition
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
FR2663224B1 (fr) 1990-06-14 1995-01-20 Applicationes Farmaceuticas Sa Forme galenique parenterale.
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
EP0569096A1 (en) 1992-05-08 1993-11-10 Akzo Nobel N.V. Depot preparation
DE669128T1 (de) 1992-11-17 1996-03-14 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung.
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2178592C (en) 1993-12-09 2009-07-28 Jurgen Engel Long-acting injection suspensions and a process for their preparation
JP3701693B2 (ja) 1993-12-28 2005-10-05 日本製薬株式会社 鎮痛薬含有注射用徐放性脂肪乳剤
US6333021B1 (en) 1994-11-22 2001-12-25 Bracco Research S.A. Microcapsules, method of making and their use
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
EG24221A (en) 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
US5776928A (en) 1995-04-21 1998-07-07 Eli Lilly And Company Method for treating dyskinesias with olanzapine
CZ292565B6 (cs) 1995-05-30 2003-10-15 Eli Lilly And Company Použití 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepinu k přípravě farmaceutického prostředku pro léčení kognitivní dysfunkce
ATE226825T1 (de) 1995-06-01 2002-11-15 Lilly Co Eli Behandlung der anorexie
US5693336A (en) 1995-06-07 1997-12-02 Nexstar Pharmaceuticals, Inc. Blood stable liposomal cyclosporin formulations
US5891461A (en) 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
JPH09157159A (ja) 1995-12-11 1997-06-17 Lion Corp カロチノイド含有組成物
ID21924A (id) 1996-09-23 1999-08-12 Lilly Co Eli Olanzapin dihidrat d
KR100537713B1 (ko) * 1997-09-30 2005-12-20 일라이 릴리 앤드 캄파니 2-메틸-티에노-벤조디아제핀 제제
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
ID29574A (id) * 1998-09-30 2001-09-06 Lilly Co Eli Formulasi 2-metil-tieno-benzodiazepin
CZ2003566A3 (cs) * 2000-08-31 2004-01-14 Dr. Reddy's Laboratories Ltd. Způsob přípravy hydrátů olanzapinu a jejich konverze na krystalické formy olanzapinu
CA2464306A1 (en) * 2001-10-29 2003-05-08 Dr. Reddy's Laboratories Ltd. Olanzapine dihydrate-ii a process for its preparation and use thereof
ES2363364T3 (es) 2005-01-05 2011-08-02 Eli Lilly And Company Dihidrato de pamoato de olanzapina.

Also Published As

Publication number Publication date
EP1838716A1 (en) 2007-10-03
JP4940152B2 (ja) 2012-05-30
WO2006073886A1 (en) 2006-07-13
SI1838716T1 (sl) 2011-10-28
US20080096871A1 (en) 2008-04-24
ATE511512T1 (de) 2011-06-15
PL1838716T3 (pl) 2011-09-30
JP2008526748A (ja) 2008-07-24
CY1111762T1 (el) 2015-10-07
ES2363364T3 (es) 2011-08-02
EP1838716B1 (en) 2011-06-01
US7932249B2 (en) 2011-04-26
PT1838716E (pt) 2011-07-15

Similar Documents

Publication Publication Date Title
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
ATE469895T1 (de) Cgrp-rezeptorantagonisten
CL2007002261A1 (es) Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
CL2007003341A1 (es) Compuestos derivados de imidazotriazinas; composicion farmaceutica, util para el tratamiento del cancer, arteroesclerosis y enfermedades cardiovasculares entre otras.
CL2007002327A1 (es) Compuestos derivados de fenil-imidazol sustituido; composicion farmaceutica; y uso en el tratamiento del vhc.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
HK1137146A1 (en) Pharmaceutical compositions comprising activin-actriia antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
CL2007002017A1 (es) Compuestos derivados de [4,5']-bipirimidinil-6,4'-diamina; composicion farmaceutica; y uso como inhibidor de la actividad de cinasa en cancer de vejiga, cancer cervical y mieloma multiple.
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
CL2007002757A1 (es) Compuestos derivados de 1,2,4-triazina sustituida; composicion farmaceutica; y uso en el tratamiento o prevencion del reflujo gastroesofagico y ansiedad.
MX2009006704A (es) Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
PT2383271E (pt) Aminoquinolonas como inibidores de gsk-3
CL2008001234A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de las proteinas de apoptosis; y uso en el tratamiento del cancer.
EA200701820A1 (ru) Применение диосметиновых соединений при лечении и профилактике тромботических патологий
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
ATE481984T1 (de) Vakzine-peptid-kombinationen gegen katzenallergie
ATE448232T1 (de) Substituierte heterozyklen
WO2009071689A3 (de) 5-halogen-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
HK1119557A1 (en) Anti-inflammatory modalities
CL2007003038A1 (es) Compuestos derivados de 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y uso en el tratamiento de trastornos vasculares oclusivos.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
CL2008000629A1 (es) Compuestos macrociclicos derivados de 6-aril-4-mercapto-[1.3.5]triazina/[1.3]pirimidin-2-amina; composicion farmaceutica, utiles en el tratamiento del cancer.
ATE531721T1 (de) Cyanoaminochinolone als gsk-3-inhibitoren
CL2007003672A1 (es) Compuestos derivados de heteroaril-pirrolidinil-cetona y heteroaril-piperidinil-cetona; composicion farmaceutica; y uso en el tratamiento de la depresion y ansiedad.